"","Blank 1","Frequency","Blank 2","Frequency"
"1","",126,"or nursing women / men of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                                             ",8
"147","patients must not be",19,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately                                                                                                                                                                                                                                                                                      ",7
"243","women must not be",17,"or suspect she is pregnant while she or her partner is participating in this study she or the participating partner should inform the treating physician immediately                                                                                                                                                                                                                                                                                                                                                                                                   ",6
"92","not",16,"or breastfeeding                                                                                                                                                                                                                                                                                                                                                                                                                            ",5
"105","female patients who are",10,"or breast feeding all fcbp must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                                        ",5
"115","patients who are",7,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with cabozantinib                                                                                                                                                                                                                                                                                                                                                                                                                ",4
"195","any of the following",6,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with nivolumab                                                                                                                                                                                                                                                                                                                                                                                                                ",4
"155","should a woman become",4,"are ineligible                                                                                                                                                                                                                                                                                                                                                                                                                           ",4
"102","female participants who are",3,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with atezolizumab                                                                                                                                                                                                                                                                                                                                                                                                                ",3
"111","female subjects of childbearing potential must not be",3,"women or nursing mothers fcbp should be advised to avoid pregnancy and use effective methods of contraception men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception if a female patient or a female partner of a patient becomes pregnant while the patient receives trametinib the potential hazard to the fetus should be explained to the patient and partner as applicable                                                                                                                                                                                                                                                                                                                                                         ",3
"73","treatment",2,"and not nursing for fcbp only a negative pregnancy test done = < 7 days prior to registration is required                                                                                                                                                                                                                                                                                                                                                                                                            ",3
"76","females who are",2,"or breast feeding all fcbp must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                                  ",3
"103","non",2,"or breast feeding                                                                                                                                                                                                                                                                                                                                                                                                                          ",3
"113","the study drug must not be administered to",2,"women nursing women men or fcbp who are unwilling to employ adequate contraception                                                                                                                                                                                                                                                                                                                                                                                                                ",3
"130","pregnancy and breast feeding female patients who are",2,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with lenalidomide                                                                                                                                                                                                                                                                                                                                                                                                                ",2
"193","fcbp fcbp must have a negative urine pregnancy test within 7 days prior to randomization enrollment female participants enrolled in the treatment arm are advised to not become",2,"and breastfeeding women are excluded from this study breastfeeding should be discontinued if the mother is treated with ibrutinib                                                                                                                                                                                                                                                                                                                                                                                                              ",2
"70","patient who is",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with ipdr                                                                                                                                                                                                                                                                                                                                                                                                                ",2
"72","woman who are",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with vx 970                                                                                                                                                                                                                                                                                                                                                                                                               ",2
"79","tumor biopsy sequencing women who are",1,"women are excluded from this study breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug                                                                                                                                                                                                                                                                                                                                                                                          ",2
"80","treatment women who are",1,"women are excluded from this study                                                                                                                                                                                                                                                                                                                                                                                                                           ",2
"81","women who are",1,"women are excluded from this study breastfeeding should be discontinued                                                                                                                                                                                                                                                                                                                                                                                                                       ",2
"87","if",1,"women and women who are breastfeeding are excluded from this study                                                                                                                                                                                                                                                                                                                                                                                                                      ",2
"106","men and fcbp and their partners must agree to use adequate contraception while enrolled on this study based on the established teratogenic potential of alkylating agents",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with cediranib or olaparib                                                                                                                                                                                                                                                                                                                                                                                                              ",2
"107","female patients of childbearing potential must not be",1,"a pregnancy test is required for female patients of childbearing potential                                                                                                                                                                                                                                                                                                                                                                                                                   ",2
"109","known pregnancy or breast feeding",1,"or breast feeding female patients of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to receiving the first dose of study medication if the urine test is positive or cannot be confirmed as negative a serum pregnancy test will be required pregnant women are excluded from this study breastfeeding should be discontinued if the mother is to be treated with mk 3475 pembrolizumab                                                                                                                                                                                                                                                                                                                                                   ",2
"114","fcbp should be advised to avoid pregnancy and use effective methods of contraception if a female patient or a female partner of a patient becomes",1,"or nursing                                                                                                                                                                                                                                                                                                                                                                                                                        ",2
"121","inclusion criteria for stratum c female subjects of childbearing potential must not be",1,"women nursing women                                                                                                                                                                                                                                                                                                                                                                                                                      ",2
"122","pregnancy or breast feeding female patients must be surgically sterile be post menopausal or must agree to use effective contraception during the period of therapy and for 90 days following the last dose of ro7009789 all female patients with reproductive potential must have a negative pregnancy test prior to enrollment women or men of reproductive potential may not participate unless they agree to use an effective contraceptive method female patients should not become",1,"women or nursing mothers                                                                                                                                                                                                                                                                                                                                                                                                                             ",2
"125","female patients of childbearing potential must have a negative urine or serum pregnancy within 72 hours before receiving the first dose of study medication if the urine test is positive or cannot be confirmed as negative a serum pregnancy test will be required note women of child bearing potential must agree to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity beginning with the screening visit and for the duration of study participation through 120 days beyond last dose of mk 3475 administration patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > = 1 year should a woman become",1,"or nursing women                                                                                                                                                                                                                                                                                                                                                                                                                              ",2
"129","fcbp should be advised to avoid becoming",1,"or breast feeding females are excluded males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method abstinence is an acceptable method of birth control                                                                                                                                                                                                                                                                                                                                                                                                ",2
"142","no patients that are known to be",1,"or breast feed a child during treatment on this protocol men must practice complete abstinence or agree to use a condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy note all participants must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure                                                                                                                                                                                                                               ",2
"145","step i the following patients will be excluded",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with abt 888                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"146","step ii the following patients will be excluded",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with abt 888 these potential risks may also apply to other agents used in this study                                                                                                                                                                                                                                                                                                                                                                                                  ",1
"149","study drug must not be administered to",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with abt 888 and sch727965                                                                                                                                                                                                                                                                                                                                                                                                             ",1
"154","fcbp must have a negative serum pregnancy test within 7 days prior to initiation of treatment women will be considered not of childbearing potential if they are surgically sterile bilateral oophorectomy or hysterectomy and / or post menopausal amenorrheic for at least 12 months should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with vorinostat                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"156","fcbp must have a negative urine pregnancy test within 7 days prior to initiation of treatment women will be considered not of childbearing potential if they are surgically sterile bilateral oophorectomy or hysterectomy and / or post menopausal amenorrheic for at least 12 months should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with veliparib this may also apply to other agents used in this study                                                                                                                                                                                                                                                                                                                                                                                                     ",1
"159","fcbp and male patients should use effective contraception during treatment with mm 398 and for 90 days following the final dose of veliparib and mm 398 for both female and male patients should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with this drug                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"175","clinical / laboratory criteria patients must not be",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with mln8237                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"177","fcbp must have a negative urine or serum pregnancy test within 28 days prior to registration women / men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with azd1775 mk 1775                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"178","fcbp must have negative serum or urine pregnancy test 7 days prior to registration and agree to use birth control throughout study and for 23 weeks after completion of protocol therapy patients must not be",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with xl184                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"179","fcbp must have a negative urine or serum pregnancy test within 28 day prior to registration women / men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with mln8237 and / or romidepsin                                                                                                                                                                                                                                                                                                                                                                                                            ",1
"183","female participants must have a negative pregnancy test within 1 week of enrollment and all participants must agree to use two reliable methods of contraception simultaneously if conception is possible during the study and for 6 months after stopping treatment should a woman subject become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with azd2171                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"184","women of child bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with belinostat                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"186","fcbp fcbp and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug for female patients and for 7 months after the last dose of study drug for male patients who are sexually active with fcbp should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with dabrafenib                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"187","randomized phase ii arms k and l fcbp fcbp and sexually active males must either abstain from sexual intercourse for the duration of their participation in the study or agree to use both double barrier contraception and birth control pills or implants for at least one week prior to the start of the study drug and continuing for 5 months after the last dose of study drug for female patients and for 7 months after the last dose of study drug for male patients who are sexually active with fcbp should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with alt 803                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"188","women of child bearing potential fcbp may be included only if acceptable contraception is in place for two weeks before study entry for the duration of the treatment with the study drug and for 2 months after the last dose of azd1775 male patients who are involved in the study must agree to avoid procreative and unprotected sex i . e . by using acceptable forms of contraception and must not donate sperm during the study and for 3 months after the last dose of azd1775 where the female partner is",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with the study drugs                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"190","men who have a female partner of childbearing potential must be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol specified therapy men who have a",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with pomalidomide                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"191","women of child bearing potential and men with a female partner of child bearing potential must agree to use adequate contraception using one of the methods listed below prior to study entry for the duration of study participation and up to 4 months following completion of therapy total abstinence from sexual intercourse minimum one complete menstrual cycle prior to study drug administration vasectomized male subject or vasectomized partner of female subjects hormonal contraceptives oral parenteral transdermal or vaginal ring for at least 3 months prior to study drug administration if the subject is currently using a hormonal contraceptive she should also use a barrier method during this study and for 1 month after study completion intrauterine device iud double barrier method male condom plus diaphragm or vaginal cap with spermicide contraceptive sponge jellies or creams men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception additionally male subjects including those who are vasectomized whose partners are",1,"women are excluded from this study breastfeeding should be discontinued prior to the mother being treated with the study drugs                                                                                                                                                                                                                                                                                                                                                                                                             ",1
"192","fcbp i . e . patients whose reproductive organs remain in place and who have not passed menopause and men must agree to use a highly effective method of contraception e . g . hormonal intrauterine device or abstinence prior to study entry during the study participation and for six months after the last dose of the drug women of child bearing potential must have a negative pregnancy test within 14 days prior to randomization cannot be breast feeding and must agree to use a highly effective form of contraception throughout the treatment period and for 6 months after the last dose of study treatment should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with this agent                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"194","fcbp must have a negative serum pregnancy test prior to study entry fcbp and men must agree to practice 1 highly effective method of contraception and 1 additional effective barrier method at the same time prior to study entry for the duration of study participation and through 90 days or longer as mandated by local labeling e . g . uspi smpc etc . after the last dose of study drug should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with mln0128 tak 228 and ziv aflibercept                                                                                                                                                                                                                                                                                                                                                                                                           ",1
"196","women of child bearing potential must have a negative serum or urine pregnancy test within 7 days unless prior hysterectomy or menopause defined as 12 consecutive months without menstrual activity patients should not become",1,"or nursing women breastfeeding should be discontinued if the mother is treated with mln0128                                                                                                                                                                                                                                                                                                                                                                                                                   ",1
"197","men and non",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with terameprocol                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"198","women of child bearing potential and men must use two forms of contraception i . e . barrier contraception and one other method of contraception at least 4 weeks prior to study entry for the duration of study participation and for at least 24 months post treatment should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with talazoparib bmn 673                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"199","women of childbearing age should avoid becoming",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with gdc 0449                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"200","women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry for the duration of study participation and 4 months after completion of the study drugs should a woman become",1,"and breastfeeding women are excluded from this study breastfeeding should be discontinued if the mother is treated with mln0128 tak 228                                                                                                                                                                                                                                                                                                                                                                                                            ",1
"201","women of child bearing potential and men must agree to practice 1 highly effective method of contraception and 1 additional effective barrier method at the same time prior to study through 90 days or longer as mandated by local labeling eg uspi smpc etc after the last dose of study drug should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with trc102                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"202","patient is currently",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with nt i7                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"203","negative serum pregnancy test result note women of child bearing potential and men must agree to use 1 highly effective method of contraception and 1 additional effective barrier method at the same time from the time of signing the informed consent through 90 days or longer as mandated by local labeling e . g . united states product insert uspi summary of product characteristics smpc etc after the last does of study drug should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with mln0128                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"204","women of child bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry for the duration of study participation and for 3 months for women and 6 months for men following the date of the last dose of azd9291 and / or necitumumab total abstinence from sexual intercourse minimum one complete menstrual cycle prior to study drug administration vasectomized male subject or vasectomized partner of female subjects hormonal contraceptives oral parenteral transdermal or vaginal ring prior to study drug administration if the subject is currently using a hormonal contraceptive she should also use a barrier method during this study and for 3 months after study completion intrauterine device iud double barrier method male condom plus diaphragm or vaginal cap with spermicide contraceptive sponge jellies or creams additionally male subjects including those who are vasectomized whose partners are",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with at13387 and paclitaxel                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"205","women of child bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry for the duration of study participation and for 3 months for women and 6 months for men following the date of the last dose of azd9291 and / or navitoclax total abstinence from sexual intercourse minimum one complete menstrual cycle prior to study drug administration vasectomized male subject or vasectomized partner of female subjects hormonal contraceptives oral parenteral transdermal or vaginal ring for at least 3 months prior to study drug administration if the subject is currently using a hormonal contraceptive she should also use a barrier method during this study and for 3 months after study completion intrauterine device iud double barrier method male condom plus diaphragm or vaginal cap with spermicide contraceptive sponge jellies or creams additionally male subjects including those who are vasectomized whose partners are",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with azd9291 and necitumumab                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"206","women of child bearing potential and men must agree to use highly effective contraception for appropriate methods of contraception prior to study entry for the duration of study participation and for at least 5 months 150 days after the last dose of study agent should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with azd9291 and navitoclax                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"208","women of child bearing potential and men must agree to practice 1 highly effective method of contraception and 1 additional effective barrier method of contraception at the same time from the time of signing the informed consent through 90 days for female patients and 120 day for male patients after the last dose of study drug or agree to completely abstain from heterosexual intercourse should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with medi 570                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"209","women of child bearing potential and male patients and their partners who are sexually active must agree to use two highly effective forms of contraception in combination for the duration of study participation and for 3 months after completion of olaparib and cediranib administration should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with methoxyamine                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"211","fertile men should be willing to use barrier contraception during and for 4 months after azd9291 osimertinib and fertile women must agree to use adequate contraceptive measures during and for 6 weeks after azd9291 osimertinib fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least 6 months after the completion of bevacizumab therapy should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with erlotinib and onalespib                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"212","female subject is",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with vx 970 these potential risks may also apply to other agents used in this study                                                                                                                                                                                                                                                                                                                                                                                                  ",1
"213","the study treatment must be excluded in the following patients female subject is",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with m6620 vx 970                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"214","fcbp must have a negative serum pregnancy test within 72 hours prior to the first dose of bal101553 fcbp must agree to use highly effective contraceptive methods for the duration of study participation and for an additional 90 days after the last dose of study drug highly effective contraceptive methods include male or female sterilization bilateral tubal occlusion or vasectomy intrauterine device iud combined estrogen and progesterone containing hormonal contraception oral vaginal ring or transdermal patch with an ethinylestradiol dose of at least 30 ug plus use of male condoms preferably with spermicides female condoms a female diaphragm or a cervical cap or total sexual abstinence should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with at13387 onalespib                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"216","women of child bearing potential and sexually active males must agree to use at least two other accepted and effective methods of contraception and / or to abstain from sexual intercourse for the duration of their participation in the study and for at least 4 weeks after treatment with dabrafenib or for 4 months after dabrafenib in combination with trametinib women of child bearing potential must use at least two other accepted and effective methods of contraception and / or to abstain from sexual intercourse for at least 5 months after the last dose of nivolumab and / or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and / or abstain from sexual intercourse for at least 7 months after the last dose of nivolumab and / or ipilimumab should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with m6620 vx 970 and / or gemcitabine                                                                                                                                                                                                                                                                                                                                                                                                          ",1
"218","quantitative serum b hcg must be negative in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with vx 970 these potential risks also apply to the other agents used in this study such as carboplatin and gemcitabine                                                                                                                                                                                                                                                                                                                                                                                             ",1
"235","general exclusion criteria for subprotocols",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with any of these agents                                                                                                                                                                                                                                                                                                                                                                                                             ",1
"244","randomized phase ii arms k and l women must not be",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with high dose nelfinavir                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"248","eligibility criteria for randomization step 1 women must not be",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated                                                                                                                                                                                                                                                                                                                                                                                                                  ",1
"251","fcbp must have a negative serum pregnancy test within 2 weeks prior to registration patients that are",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with sgi 110                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"260","a female of childbearing potential is a sexually mature female who 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months fcbp must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mlu / ml no more than 14 days prior to registration and must agree to repeat this test within 24 hours of starting pomalidomide must either commit to complete abstinence from heterosexual contact or begin two acceptable methods of birth control one highly effective method and one additional effective barrier method at the same time before starting pomalidomide must agree to ongoing pregnancy testing must agree to not become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with dasatinib                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"261","re registration eligibility criteria step 2 fcbp must have a negative serum or urine pregnancy test within 72 hours prior to re registration must either commit to complete abstinence from heterosexual contact or begin two acceptable methods of birth control one highly effective method and one additional effective barrier method at the same time before starting pomalidomide must agree to ongoing pregnancy testing must agree to not become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with selumetinib                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"262","female who is able to become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab these potential risks may also apply to blinatumomab                                                                                                                                                                                                                                                                                                                                                                                                      ",1
"276","women of child bearing potential fcbp must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation fcbp should use an adequate method to avoid pregnancy for 31 weeks after the last dose of investigational drug fcbp must have a negative serum or urine pregnancy test minimum sensitivity 25 iu / l or equivalent units of hcg hcg within 24 hours prior to the start of nivolumab women must not be breastfeeding women who are not of childbearing potential i . e . who are postmenopausal or surgically sterile do not require contraception fcbp fcbp is defined as any female who has experienced menarche and who has not undergone surgical sterilization hysterectomy or bilateral oophorectomy or who is not postmenopausal menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes in addition women under the age of 55 must have a documented serum follicle stimulating hormone fsh level less than 40 miu / ml fcbp receiving nivolumab will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product these durations have been calculated using the upper limit of the half life for nivolumab 25 days and are based on the protocol requirement that fcbp use contraception for 5 half lives plus 30 days should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with medi4736 durvalumab tremelimumab and radiation                                                                                                                                                                                                                                                                                                                                                                                                            ",1
"278","fcbp fcbp and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation fcbp should use an adequate method to avoid pregnancy for 6 months after the last dose of investigational drug fcbp must have a negative serum or urine pregnancy test minimum sensitivity 25 iu / l or equivalent units of human chorionic gonadotropic hcg within 72 hours prior to the start of nivolumab women must not be breastfeeding men who are sexually active with fcbp must use any contraceptive method with a failure rate of less than 1 per year men receiving nivolumab and who are sexually active with fcbp will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product women who are not of childbearing potential i . e . who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception fcbp receiving nivolumab will be instructed to adhere to contraception for a period of 6 months after the last dose of investigational product men receiving nivolumab and who are sexually active with fcbp will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with ipilimumab                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"280","women of child bearing potential fcbp and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation fcbp should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug fcbp must have a negative serum or urine pregnancy test minimum sensitivity 25 iu / l or equivalent units of hcg hcg within 24 hours prior to the start of treatment on the study women must not be breastfeeding men who are sexually active with fcbp must use any contraceptive method with a failure rate of less than 1 per year men receiving nivolumab / ipilimumab and blinatumomab and who are sexually active with fcbp will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product women who are not of childbearing potential i . e . who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception note fcbp fcbp is defined as any female who has experienced menarche and who has not undergone surgical sterilization hysterectomy or bilateral oophorectomy or who is not postmenopausal menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes in addition women under the age of 55 must have a documented serum follicle stimulating hormone fsh level less than 40 miu / ml should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with atezolizumab and / or bevacizumab                                                                                                                                                                                                                                                                                                                                                                                                            ",1
"281","fcbp fcbp is defined as any female who has experienced menarche and who has not undergone surgical sterilization hysterectomy or bilateral oophorectomy or who is not postmenopausal menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes fcbp and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry during the study participation and for four months after the last dose of the drug fcbp must have a negative serum pregnancy test within 72 hours prior to enrollment and agree to use effective contraception throughout the treatment period and for 4 months after the last dose of study treatment should a woman become",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with bal101553                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"283","the following categories are ineligible",1,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with pt2385                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"288","any of the following nursing women",1,"and / or breastfeeding                                                                                                                                                                                                                                                                                                                                                                                                                          ",1
"290","fcbp must not be known to be",1,"or lactating women                                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"2","",NA,"                                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"3","",NA,"women are eligible to participate in this study                                                                                                                                                                                                                                                                                                                                                                                                                         ",1
"4","",NA,"or breastfeeding are ineligible                                                                                                                                                                                                                                                                                                                                                                                                                          ",1
"5","",NA,"and breastfeeding women are excluded from this study                                                                                                                                                                                                                                                                                                                                                                                                                         ",1
"6","",NA,"or breastfeeding women                                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"7","",NA,"women are excluded breastfeeding should be discontinued prior to the first dose of study drug and women should refrain from nursing throughout the treatment period and for 3 months following the last dose of study drug                                                                                                                                                                                                                                                                                                                                                                                             ",1
"8","",NA,"or breastfeeding or expecting to conceive or father children within the projected duration of the trial starting with the pre screening or screening visit through 120 days after the last dose of trial treatment pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with mk 3475                                                                                                                                                                                                                                                                                                                                                                           ",1
"9","",NA,"women are excluded from this study breastfeeding should be discontinued prior to treatment with dabrafenib / trametinib                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"10","",NA,"or nursing with negative serum pregnancy test pregnant women are excluded from this study breastfeeding should be discontinued timeline within 3 weeks prior to enrollment                                                                                                                                                                                                                                                                                                                                                                                                       ",1
"11","",NA,"women                                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"12","",NA,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with cediranib and olaparib                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"13","",NA,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumab                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"14","",NA,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with olaparib or cediranib                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"15","",NA,"women are excluded from this study breastfeeding should be discontinued if the mother is treated with olaparib or at13387                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"16","",NA,"women are excluded breastfeeding should be discontinued if the mother is treated with cediranib and olaparib                                                                                                                                                                                                                                                                                                                                                                                                                 ",1
"17","",NA,"or breastfeeding fcbp must have a negative urine or serum pregnancy test within 72 hours prior to randomization all fcbp must be willing to comply with an acceptable birth control regimen to prevent pregnancy while receiving treatment and for 3 months after treatment is discontinued as determined by the investigator post menopausal women must be amenorrheic for at least 12 months to be considered of non childbearing potential note a woman of childbearing potential is one who is biologically capable of becoming pregnant this includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives                                                                                                                                                                                                                                                                                                                         ",1
"18","",NA,"and non lactating patients of child bearing potential must have a negative pregnancy test within 7 days prior to registration perimenopausal patients must be amenorrheic > = 12 months to be considered not of child bearing potential                                                                                                                                                                                                                                                                                                                                                                                           ",1
"19","",NA,"female patients are not eligible for this study                                                                                                                                                                                                                                                                                                                                                                                                                         ",1
"20","",NA,"women will be excluded from this study female patients who are lactating must agree to stop breastfeeding or will otherwise be excluded from this study fcbp must have a negative pregnancy test to be eligible for this study                                                                                                                                                                                                                                                                                                                                                                 ",1
"21","",NA,"or breast feeding female patients of childbearing potential must have a negative serum or urine pregnancy test                                                                                                                                                                                                                                                                                                                                                                                                        ",1
"22","",NA,"or breast feeding confirmation that the subject is not pregnant must be established by a negative serum beta b hcg b hcg or urine pregnancy test result obtained during screening pregnancy testing is not required for post menopausal or surgically sterilized women                                                                                                                                                                                                                                                                                                                                                                                   ",1
"23","",NA,"women are excluded as the effects of 18f flt on the fetus are not known and there is the potential for teratogenic or abortifacent effects within 48 hours prior to a pet scan a pregnancy test will be obtained in all female participants of child bearing potential to confirm non pregnant status because there is an unknown but potential risk of adverse effects in nursing infants breastfeeding should be discontinued before the mother receives 18f flt                                                                                                                                                                                                                                                                                                                                                ",1
"24","",NA,"or breast feeding female subjects of childbearing potential must have a negative serum or urine pregnancy test pregnancy test must be repeated within 72 hours prior to the start of therapy                                                                                                                                                                                                                                                                                                                                                                                          ",1
"25","",NA,"are not eligible pregnancy tests must be obtained in girls who are post menarchal                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"26","",NA,"while the patient receives trametinib the potential hazard to the fetus should be explained to the patient and partner as applicable                                                                                                                                                                                                                                                                                                                                                                                   ",1
"27","",NA,"pregnancy test is required for female patients of childbearing potential                                                                                                                                                                                                                                                                                                                                                                                                                    ",1
"28","",NA,"a negative pregnancy test is required for female patients of childbearing potential                                                                                                                                                                                                                                                                                                                                                                                                                  ",1
"29","",NA,"at screening fcbp are defined as premenopausal females capable of becoming pregnant ie females who have had any evidence of menses in the past 12 months with the exception of those who had prior hysterectomy however women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy antiestrogens low body weight ovarian suppression or other reasons                                                                                                                                                                                                                                                                                                                                                 ",1
"30","",NA,"are excluded patients should not be pregnant or plan to become pregnant while on treatment a pregnancy test prior to enrollment is required for female patients of childbearing potential                                                                                                                                                                                                                                                                                                                                                                                                ",1
"31","",NA,"while participating in this research study or for 90 days following therapy male patients should not father a child while in this research study or for 90 days following therapy                                                                                                                                                                                                                                                                                                                          ",1
"32","",NA,"are not eligible note a pregnancy test is required for female patients of childbearing potential prior to study entry                                                                                                                                                                                                                                                                                                                                                                                                          ",1
"33","",NA,"are not eligible fcbp require a negative pregnancy test prior to starting study drug                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"34","",NA,"while receiving ino women should not breast feed during treatment with ino and for at least 2 months after the final dose female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days of starting protocol therapy female patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of their study participation and for 8 months after the last dose of ino men with female partners of childbearing potential should use effective contraception during treatment with ino and for at least 5 months after the last dose of ino lactating females are not eligible unless they agree not to breastfeed their infants                                                                                                                                                                                                                                                                                             ",1
"35","",NA,"a pregnancy test is required for female patients of childbearing potential lactating females who plan to breastfeed their infants sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation                                                                                                                                                                                                                                                                                                                                                                               ",1
"36","",NA,"and not nursing for fcbp only a negative serum pregnancy test done = < 7 days prior to registration is required                                                                                                                                                                                                                                                                                                                                                                                                           ",1
"37","",NA,"and not nursing fcbp only a negative pregnancy test done = < 7 days prior to registration is required                                                                                                                                                                                                                                                                                                                                                                                                             ",1
"38","",NA,"or nursing fcbp must have a negative serum pregnancy test performed within 7 days prior to the start of study therapy note pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with azd1775 / belinostat                                                                                                                                                                                                                                                                                                                                                                                       ",1
"39","",NA,"and not nursing therefore for fcbp only a negative pregnancy test done = < 7 days prior to re registration is required                                                                                                                                                                                                                                                                                                                                                                                                          ",1
"40","",NA,"and not nursing for fcbp only a negative urine or serum pregnancy test done = < 14 days prior to registration and confirmation they are not nursing is required                                                                                                                                                                                                                                                                                                                                                                                                   ",1
"41","",NA,"and not nursing for fcbp only a negative urine or serum pregnancy test done = < 8 days prior to registration is required                                                                                                                                                                                                                                                                                                                                                                                                         ",1
"42","",NA,"and non nursing women and men of reproductive potential should agree to use an effective means of birth control                                                                                                                                                                                                                                                                                                                                                                                                             ",1
"43","",NA,"or nursing note peri menopausal women must be amenorrheic for > = 12 months to be considered not of childbearing potential                                                                                                                                                                                                                                                                                                                                                                                                        ",1
"44","",NA,"or nursing patients                                                                                                                                                                                                                                                                                                                                                                                                                              ",1
"45","",NA,"or nursing female patients are excluded from this study                                                                                                                                                                                                                                                                                                                                                                                                                        ",1
"46","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately the potential hazard to the fetus should be explained to the patient and partner as applicable                                                                                                                                                                                                                                                                                                                                           ",1
"47","",NA,"or nursing women of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                                               ",1
"48","",NA,"or nursing women / men of reproductive potential must have agreed to use an effective contraceptive method during the study period a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                                         ",1
"49","",NA,"or nursing women / men of reproductive potential must have agreed to use an effective non hormonal contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation corresponding procedures for men include castration vasectomy and barrier contraceptive devices however if at any point a previously celibate patient chooses to become heterosexually active during the protocol therapy he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                                         ",1
"50","",NA,"or nursing women / men of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation hormonal contraception is not allowed however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                                        ",1
"51","",NA,"or nursing women / men of reproductive potential must agree to use an effective contraceptive method during and for 6 months after completing protocol treatment a negative pregnancy test either serum or urine is required within 7 days prior to registration a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                     ",1
"52","",NA,"or nursing women / men of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures hormonal contraception is not allowed                                                                                                                                                                                                                                                                                                        ",1
"53","",NA,"or nursing women / men of reproductive potential must have agreed to use an effective contraceptive method for up to 3 months after the final administered dose of chemotherapy a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                                     ",1
"54","",NA,"or nursing men and women of reproductive potential must have agreed to use an effective contraceptive method a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                                             ",1
"55","",NA,"or nursing women / men of reproductive potential must have agreed to use an effective contraceptive method hormonal or barrier method of birth control abstinence prior to study entry during the study participation and for 4 months after the last dose of the drug a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                              ",1
"56","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures patients must not be pregnant or nursing                                                                                                                                                                                                                                                  ",1
"57","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy bilateral tubal ligation or vasectomy however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures patients must not be pregnant or nursing                                                                                                                                                                                                                                                 ",1
"58","",NA,"or nursing women of reproductive potential must have a negative serum pregnancy test within 7 days prior to registration women / men of reproductive potential must have agreed to use an effective contraceptive method while on study and for 120 days after last study treatment a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol he / she is responsible for beginning contraceptive measures                                                                                                                                                                                                                                                                                 ",1
"59","",NA,"or nursing females of reproductive potential must have negative serum pregnancy test within 2 days prior to registration and agree to use an effective contraceptive method throughout the study and for 5 months after completion of protocol treatment a woman is considered to be of reproductive potential if she has had menses at any time in the preceding 12 consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with a side effect of pregnancy prevention defined as a hysterectomy bilateral oophorectomy or bilateral tubal ligation if at any point a previously celibate patient chooses to become heterosexually active during or within 5 months after protocol treatment she is responsible for beginning effective contraceptive measures                                                                                                                                                                                                                                                                                               ",1
"60","",NA,"women are excluded from this research the male partner should use a condom females of child bearing potential must be willing to utilize one of the more effective birth control methods during the study unless female has had a hysterectomy or tubal ligation                                                                                                                                                                                                                                                                                                                                                                                     ",1
"61","",NA,"or suspect she is pregnant while the subject is participating in this study she should inform her treating physician immediately the participant will then be removed from protocol therapy participants who father a child while participating in the study will be permitted to continue with the protocol the participant however is required to notify the investigator if he fathers a child                                                                                                                                                                                                                                                                                                                       ",1
"62","",NA,"or suspect she is pregnant while she is participating in this study she should inform her treating physician immediately sexually active subjects must agree to use medically accepted barrier methods of contraception e . g . male or female condom during the course of the study and for 4 months after the last dose of study drug s even if oral contraceptives are also used all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug s                                                                                                                                                                                                                                                                                                ",1
"63","",NA,"women are excluded from this trial nursing women are also excluded fcbp must agree to either abstain from sexual intercourse or use two forms of acceptable birth control including one barrier method for 4 weeks prior to study entry for the duration of study participation and for 3 months after completion of study men must use a latex condom every time they have sexual intercourse during therapy and for 3 months after study completion even if they have had a successful vasectomy should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study she or her partner should inform the treating physician immediately                                                                                                                                                                                                                                                                                                                 ",1
"64","",NA,"or not using effective birth control men should be advised to abstain while in the study and for 3 months after the last dose of azd1775 female partners who are of child bearing potential of men participating in clinical studies of azd1775 will also be required to use effective contraceptive measures while their partner is on study drug and for 3 months thereafter male patients will be advised to arrange for the freezing of sperm samples prior to the start of the study should they wish to father children while on azd1775 or during the 3 months after stopping azd1775                                                                                                                                                                                                                                  ",1
"65","",NA,"or breast feeding women of child bearing potential must agree to use adequate contraception hormonal or barrier method of birth control abstinence not having sex oral contraceptives intrauterine device iud depo provera tubal ligation or vasectomy of the partner with confirmed negative sperm counts in a monogamous relationship same partner an acceptable although less reliable method involves the careful use of condoms and spermicidal foam or gel and / or cervical cap or sponge prior to study entry and for the duration of study participation should a woman become pregnant or suspect she is pregnant while participating in this study she should inform her study physician immediately women who are currently breast feeding are not eligible for this study                                                                                                                                                                                                                                                                                                          ",1
"66","",NA,"partner must be willing to use a condom during sexual activity throughout protocol therapy and for 3 months after the last dose of protocol specified therapy                                                                                                                                                                                                                                                                                                                                                            ",1
"67","",NA,"or might be pregnant must agree to use condoms for the duration of the study and for 4 months following completion of therapy                                                                                                                                                                                                                                   ",1
"68","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately abstinence is only acceptable when this is in line with the preferred and usual lifestyle of the patient                                                                                                                                                                                                                                                                            ",1
"69","",NA,"during study participation all fcbp must agree to either commit to continued abstinence from heterosexual intercourse or to use a reliable birth control method during heterosexual intercourse oral contraceptive pills intrauterine device nexplanon depoprovera or bilateral tubal ligation etc . or another acceptable method as determined by the investigator during the entire period of the trial 5 years or more and must not intend to become pregnant during study participation and for 3 months after treatment is discontinued if the participant is enrolled in the treatment arm female participants if engaging in heterosexual intercourse must be willing to comply with an acceptable birth control regimen as determined by the investigator                                                                                                                                                                                                                                                                                       ",1
"71","",NA,"or suspect she is pregnant while participating in this study she should inform her treating physician immediately men treated or enrolled on this protocol must also agree to use highly effective barrier contraception prior to the study for the duration of study participation and through 120 days after the last dose of study drug                                                                                                                                                                                                                                                                                                ",1
"74","",NA,"women nursing women fcbp who are unwilling to employ adequate contraception note should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately women of child bearing potential and men must agree to use adequate contraception using one of the methods listed below prior to study entry for the duration of study participation and up to 90 days following completion of therapy total abstinence from sexual intercourse minimum one complete menstrual cycle prior to study drug administration vasectomized male subject or vasectomized partner of female subjects hormonal contraceptives oral parenteral transdermal or vaginal ring for at least 3 months prior to study drug administration if the subject is currently using a hormonal contraceptive she should also use a barrier method during this study and for 1 month after study completion intrauterine device iud double barrier method male condom plus diaphragm or vaginal cap with spermicide contraceptive sponge jellies or creams additionally male subjects including those who are vasectomized whose partners are pregnant or might be pregnant must agree to use condoms for the duration of the study and for 90 days following completion of therapy                                                                                                                                                                                                                    ",1
"75","",NA,"or breastfeed while on this study women of child bearing potential must agree to use 1 highly effective method of contraception and 1 additional effective barrier method at the same time from the time of signing the informed consent through 90 days or longer as mandated by local labeling e . g . united surgical partners international uspi summary of product characteristics smpc etc after the last dose of study drug or agree to practice true abstinence should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately male patients even if surgically sterilized i . e . status post vasectomy who agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug or agree to completely abstain from heterosexual intercourse                                                                                                                                                                                                                                         ",1
"77","",NA,"non breast feeding women may be enrolled if they are willing to use 2 methods of birth control or are considered highly unlikely to conceive highly unlikely to conceive is defined as 1 surgically sterilized or 2 postmenopausal a woman who is > = 45 years of age and has not had menses for greater than 2 years will be considered postmenopausal or 3 not heterosexually active for the duration of the study the two birth control methods can be barrier method or a barrier method plus a hormonal method to prevent pregnancy patients should start using birth control from study visit 1 throughout the study period up to 120 days after the last dose of study therapy the following are considered adequate barrier methods of contraception diaphragm condom by the partner copper intrauterine device sponge or spermicide appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and / or a progestational agent including oral subcutaneous intrauterine or intramuscular agents patients should continue contraceptive measures for 6 months from the last dose of all study medications                                                                                                                                                                                                                                        ",1
"78","",NA,"or suspect she is pregnant while participating in this study she should inform her treating physician immediately fcbp are required to have a negative serum pregnancy test with a sensitivity of at least 25 miu / ml within 7 days prior to the first dose of gdc 0449 serum or urine a pregnancy test serum or urine will be administered every 4 weeks if their menstrual cycles are regular or every 2 weeks if their cycles are irregular while on study within the 24 hour period prior to the administration of gdc 0449 a positive urine test must be confirmed by a serum pregnancy test prior to dispensing gdc 0449 the investigator must confirm and document the patient s use of two contraceptive methods dates of negative pregnancy test and confirm the patient s understanding of gdc 0449 cause serious or life threatening birth defects patients must continue highly effective contraception during therapy and for 24 months after the last dose of gdc 0449 fcbp are defined as follows patients with regular menses patients with amenorrhea irregular cycles or using a contraceptive method that precludes withdrawal bleeding women who have had a tubal ligation women are considered not to be of childbearing potential for the following reasons the patient has undergone hysterectomy and / or bilateral oophorectomy the patient is post menopausal defined by amenorrhea for at least 12 months in a woman > = 45 years old male patients should use condoms with spermicide even after a vasectomy during sexual intercourse with female partners while being treated with gdc 0449 and for 3 months after the last dose to avoid exposing an embryo or fetus to gdc 0449                                                                                       ",1
"82","",NA,"while taking any mtor inhibitor including mln0128 tak 228 female patients must be postmenopausal for at least 1 year before the screening visit or be surgically sterile or if they are of childbearing potential agree to practice 1 highly effective method of contraception and 1 additional effective barrier method at the same time from the time of signing the informed consent through 90 days or longer as mandated by local labeling e . g . united states product insert uspi summary of product characteristics smpc etc . after the last dose of study drug or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the patient note periodic abstinence e . g . calendar ovulation symptothermal postovulation methods withdrawal spermicides only and lactational amenorrhea are not acceptable methods of contraception female and male condoms should not be used together male patients even if surgically sterilized i . e . status postvasectomy must agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the patient note periodic abstinence e . g . calendar ovulation symptothermal postovulation methods for the female partner withdrawal spermicides only and lactational amenorrhea are not acceptable methods of contraception female and male condoms should not be used together and agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug                                                                                                                                                 ",1
"83","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study for the duration of study participation and 4 months after completion of trc102 pemetrexed and cisplatin administration non childbearing potential is defined as by other than medical reasons > = 45 years of age and has not had menses for > = 2 years amenorrheic for < 2 years without hysterectomy and oophorectomy and a follicle stimulating hormone value in the postmenopausal range upon pretrial screening evaluation or post hysterectomy oophorectomy or tubal ligation documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by mcLtrasound tubal ligation must be confirmed with medical records of the actual procedure otherwise the patient must be willing to use 2 adequate barrier methods throughout the study starting with the screening visit though 4 months after the last dose of study drugs                                                                                                                                                                                                       ",1
"84","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately any woman who becomes pregnant while receiving mln0128 tak 228 will be removed from the trial men treated or enrolled on this protocol must also agree to use highly effective barrier contraception prior to the study for the duration of study participation and 120 days after completion of mln0128 tak 228 administration men must agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug                                                                                                                                                                                                                                                                       ",1
"85","",NA,"patient must agree to use two forms of birth control if they are of child bearing potential                                                                                                                                                                                                                                                                                                                                                                                                             ",1
"86","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately men treated or enrolled on this protocol must also agree to use highly effective barrier contraception prior to the study for the duration of study participation and 4 months after completion of mln0128 tak 228 administration                                                                                                                                                                                                                                                                                          ",1
"88","",NA,"or might be pregnant must agree to use condoms for the duration of the study and for 6 months following completion of therapy                                                                                                                                                                                                                                                      ",1
"89","",NA,"or might be pregnant must agree to use condoms for the duration of the study and 6 months following completion of therapy                                                                                                                                                                                                                                                  ",1
"90","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately men treated or enrolled on this protocol must also agree to use two highly effective forms of contraception in combination prior to the study for the duration of study participation and for at least 5 months 150 days after completion of atezolizumab and / or olaparib administration women of child bearing potential negative serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1postmenopausal or evidence of non childbearing status for fcbp postmenopausal is defined as amenorrheic for 1 year or more following cessation of exogenous hormonal treatments luteinizing hormone lh and follicle stimulating hormone fsh levels in the post menopausal range for women under 50 radiation induced oophorectomy with last menses > = 1 year ago chemotherapy induced menopause with > = 1 year interval since last menses surgical sterilization bilateral oophorectomy or hysterectomy                                                                                                                                                                                                              ",1
"91","",NA,"or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab tremelimumab combination therapy whichever is later                                                                                                                                                                                                                                                                                                                                                                               ",1
"93","",NA,"or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately men must agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug                                                                                                                                                                                                                                                                                                              ",1
"94","",NA,"breastfeeding or plan to become pregnant sexually active patients and their partners must be willing to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry during the study participation and for four months after the last dose of t vec                                                                                                                                                                                                                                                                                                                                                                                ",1
"95","",NA,"or suspect she is pregnant while she or her partner is participating in this study the patient should inform the treating physician immediately                                                                                                                                                                                                                                                                                                                                         ",1
"96","",NA,"or breast feeding or planning to become pregnant during study treatment and through 7 months after the last dose of treatment female subject of childbearing potential who is unwilling to use acceptable method s of effective contraception during study treatment and through 7 months after the last dose of treatment sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec                                                                                                                                                                                                                                                                                                                                          ",1
"97","",NA,"or breast feeding or planning to become pregnant during study treatment and through 4 months after the last dose of talimogene laherparepvec female subject of childbearing potential who is unwilling to use acceptable method s of effective contraception during study treatment and through 4 months after the last dose of talimogene laherparepvec sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec                                                                                                                                                                                                                                                                                                                              ",1
"98","",NA,"or suspect she is pregnant while participating in this study she should inform her treating physician immediately male patients must agree not to donate sperm from the first dose of study drug until 90 days after the last dose of study drug male patients without a vasectomy and with a partner of childbearing potential must agree to use condoms during the study and for at least 90 days after the last dose of study drug the patient should be instructed that their female partner should use another form of contraception for the duration of the study and continue this use for at least 90 days after the last dose of study drug                                                                                                                                                                                                   ",1
"99","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal women of child bearing potential and their partners should agree to use two 2 highly effective forms of contraception throughout study participation and for at least one 1 month after the last dose of olaparib male study participants should avoid fathering a child or donating sperm during the study and for three 3 months after the last dose of olaparib                                                                                                                                                                                                                                                                                                                                               ",1
"100","",NA,"or suspect she is pregnant while she is participating in this study she should inform her treating physician immediately                                                                                                                                                                                                                                                                ",1
"101","",NA,"women will not be entered on this study pregnancy tests must be obtained in female patients who are post menarchal lactating females may not participate unless they have agreed not to breastfeed their infants males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of the study treatment                                                                                                                                                                                                                                                                                                                                                                     ",1
"104","",NA,"or breast feeding women will not be entered on this study                                                                                                                                                                                                                                                                                                                                                                                      ",1
"108","",NA,"or nursing because of the potentially harmful effects of these agents on a developing fetus women / men of reproductive potential must have agreed to use an effective contraceptive method                                                                                                                                                                                                                                                                                                                                                                                               ",1
"110","",NA,"or breast feeding females are excluded pregnancy tests must be obtained prior to enrollment for all fcbp as per institutional standards at national institutes of health nih subjects 9 years and older or those showing pubertal development males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method abstinence is an acceptable method of birth control                                                                                                                                                                                                                                                                                                                                                                 ",1
"112","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method                                                                                                                                                                                                                                                                                                                                                                                        ",1
"116","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive use two effective methods of birth control including a medically accepted barrier method of contraceptive method e . g . male or female condom for the entire period in which they are receiving protocol therapy abstinence is an acceptable method of birth control                                                                                                                                                                                                                                                                                                                                              ",1
"117","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use a highly effective method of contraception during protocol therapy and for at least 3 months after the last dose of ramucirumab a highly effective method of contraception is defined as one that results in a low failure rate that is < 1 per year when used consistently and correctly barrier methods used alone are not highly effective methods of contraception for female patients if a barrier method is used a hormonal method must be used with it to ensure that pregnancy does not occur abstinence is an acceptable method of birth control those who become pregnant while on treatment with ramucirumab must discontinue immediately and consult their treating physician                                                                                                                                                                                                                                                                               ",1
"118","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method both during and for 3 months after participation in this study abstinence is an acceptable method of contraception                                                                                                                                                                                                                                                                                                                                                                      ",1
"119","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method both during and for 3 months after participation in this study abstinence is an acceptable method of contraception those who become pregnant while on treatment with entinostat must discontinue immediately and consult their treating physician                                                                                                                                                                                                                                                                                                                                                     ",1
"120","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control a medically accepted barrier method of contraceptive method e . g . male or female condom and a second effective method of birth control during protocol therapy and for at least 4 months after the last dose of xl184 abstinence is an acceptable method of birth control                                                                                                                                                                                                                                                                                                                                        ",1
"123","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method both during and for 6 months after participation in this study abstinence is an acceptable method of contraception                                                                                                                                                                                                                                                                                                                                                                      ",1
"124","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment and for one week after the last dose of ensartinib                                                                                                                                                                                                                                                                                                                                                                        ",1
"126","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment and for 6 months after the last dose of vemurafenib                                                                                                                                                                                                                                                                                                                                                                        ",1
"127","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment                                                                                                                                                                                                                                                                                                                                                                                  ",1
"128","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while receiving study treatment and for 3 months after the last dose of ly3023414                                                                                                                                                                                                                                                                                                                                                                          ",1
"131","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment males with sexual partners who are pregnant or who could become pregnant i . e . women of child bearing potential should use effective methods of contraception for 12 weeks after completing the study to avoid pregnancy and / or potential adverse effects on the developing embryo                                                                                                                                                                                                                                                                                                                                     ",1
"132","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in females who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method                                                                                                                                                                                                                                                                                                                                                                                   ",1
"133","",NA,"or nursing if patients are of reproductive age and have not undergone hysterectomy they must use an effective contraceptive method for the duration of this study                                                                                                                                                                                                                                                                                                                                                                                                    ",1
"134","",NA,"a pregnancy test is required for female patients of childbearing potential lactating females who plan to breastfeed their infants while on study therapy and through 5 months after completion of study therapy sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for 5 months after the end of study treatment                                                                                                                                                                                                                                                                                                                                                        ",1
"135","",NA,"and not nursing fcbp must have negative urine or serum pregnancy test within 7 days of registration but before start of treatment a female of childbearing potential is a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 12 consecutive months i . e . has had menses at any time in the preceding 12 consecutive months                                                                                                                                                                                                                                                                                                                                                           ",1
"136","",NA,"and not nursing for fcbp only a negative pregnancy test done = < 7 days prior to registration is required a female of childbearing potential is a sexually mature female who has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 12 consecutive months i . e . has had menses at any time in the preceding 12 consecutive months                                                                                                                                                                                                                                                                                                                                                             ",1
"137","",NA,"during study participation all fcbp must agree to either commit to continued abstinence from heterosexual intercourse or to use a reliable birth control method during heterosexual intercourse oral contraceptive pills intrauterine device nexplanon depoprovera or bilateral tubal ligation etc . or another acceptable method as determined by the investigator during the entire period of the trial 5 years or more and must not intend to become pregnant during study participation and for 3 months after treatment is discontinued if the participant is enrolled in the treatment arm female participants if engaging in heterosexual intercourse must be willing to comply with an acceptable birth control regimen as determined by the investigator a female of childbearing potential is a sexually mature woman who 1 has not undergone a hysterectomy or bilateral oophorectomy 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                       ",1
"138","",NA,"and not nursing a female of childbearing potential is a sexually mature female who 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 12 consecutive months i . e . has had menses at any time in the preceding 12 consecutive months                                                                                                                                                                                                                                                                                                                                                                            ",1
"139","",NA,"and not nursing a female of childbearing potential is a sexually mature female who 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 12 consecutive months i . e . has had menses at any time in the preceding 12 consecutive months for fcbp only a negative pregnancy test done = < 5 days prior to registration is required                                                                                                                                                                                                                                                                                                                                                           ",1
"140","",NA,"or breast feeding all fcbp must have a blood test or urine study within 24 hours prior to enrollment to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                                 ",1
"141","",NA,"or breast feeding and must not become pregnant or breastfeed during protocol therapy and for at least 3 months after protocol therapy woman of childbearing potential must abstain from sexual activity or be willing to use 2 highly effective forms of contraception throughout protocol therapy and for at least an additional 3 months after the last dose of protocol specified therapy all fcbp must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                ",1
"143","",NA,"or breast feeding all fcbp must have a blood test or urine study = < 2 weeks prior to randomization a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                                           ",1
"144","",NA,"or breast feeding are excluded a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                                               ",1
"148","",NA,"or breast feeding . all fcbp must have a blood test or urine study within 7 days prior to fes pet / ct scan and 18f fluorodeoxyglucose fdg pet / ct scan to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                             ",1
"150","",NA,"or breast feeding fcbp must have a blood or urine study within 2 weeks prior to randomization to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                                          ",1
"151","",NA,"or breast feeding all fcbp who are uncertain if they could be pregnant or may be pregnant or as per local site standard of practice in women undergoing dbt and mri must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                              ",1
"152","",NA,"or breast feeding all fcbp must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                                          ",1
"153","",NA,"or breast feeding all fcbp must have a blood test or urine study within 7 days of registration to rule out pregnancy a female of childbearing potential is any woman regardless of sexual orientation or whether they have undergone tubal ligation who meets the following criteria 1 has not undergone a hysterectomy or bilateral oophorectomy or 2 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time in the preceding 24 consecutive months                                                                                                                                                                                                                                                                                                                                         ",1
"157","",NA,"must have a negative pregnancy test with a sensitivity of at least 25 miu / ml within 10 14 days prior to and again within 24 hours of starting pomalidomide female who is able to become pregnant must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective and one additional effective method at the same time female who is able to become pregnant must agree to ongoing pregnancy testing men must agree to use a latex condom during sexual contact with female who is able to become pregnant even if they had vasectomy for the duration of study participation and 28 days after completion of pomalidomide administration all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure while taking pomalidomide should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately                                                                                                                                                                                                                                                    ",1
"158","",NA,"and not nursing fcbp fcbp defined as a female who 1 has achieved menarche first menstrual cycle at some point or 2 has not undergone a hysterectomy the surgical removal of the uterus or bilateral oophorectomy the surgical removal of both ovaries or 3 has not been naturally postmenopausal for at least 24 consecutive months i . e . has had menses at any time during the preceding 24 consecutive months must have a negative serum or urine pregnancy test with a sensitivity of a least 50 miu / ml within 10 14 days prior to registration and again within 24 hours of starting lenalidomide must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective method and one additional effective method at the same time at least 28 days before she starts taking lenalidomide must agree to ongoing pregnancy testing men must agree to use a latex condom during sexual contact with a fcbp even if they have had a vasectomy                                                                                                                                                                                                                                                     ",1
"160","",NA,"or breast feeding are not eligible for this study                                                                                                                                                                                                                                                                                                                                                                                                                     ",1
"161","",NA,"or breast feeding women may not be entered on this study pregnancy tests must be obtained in girls who are post menarchal negative serum or urine pregnancy test within 3 days prior to enrollment                                                                                                                                                                                                                                                                                                                                                                                               ",1
"162","",NA,"or breast feeding women may not be entered on this study pregnancy tests must be obtained in girls who are post menarchal                                                                                                                                                                                                                                                                                                                                                                                                           ",1
"163","",NA,"lactating or breast feeding                                                                                                                                                                                                                                                                                                                                                                                                                         ",1
"164","",NA,"women or women who are breast feeding are not eligible for the study                                                                                                                                                                                                                                                                                                                                                                                                                    ",1
"165","",NA,"or breast feeding females lactating females must agree not to breast feed while taking the study drugs                                                                                                                                                                                                                                                                                                                                                                                                                ",1
"166","",NA,"or lactating women or fcbp and men who are sexually active and not willing / able to use medically acceptable forms of contraception                                                                                                                                                                                                                                                                                                                                                                                                          ",1
"167","",NA,"or lactating women or fcbp and male participants who are sexually active and not willing / able to use medically acceptable forms of contraception                                                                                                                                                                                                                                                                                                                                                                                                         ",1
"168","",NA,"or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal fcbp fcbp receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of nivolumab men receiving nivolumab and who are sexually active with fcbp will be instructed to adhere to contraception for a period of 7 months after the last dose of nivolumab                                                                                                                                                                                                                                                                                                                                                       ",1
"169","",NA,"or suspect she is pregnant while participating in this study she should inform the treating physician immediately                                                                                                                                                             ",1
"170","",NA,"or nursing women of child bearing potential fcbp must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation fcbp should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug fcbp must have a negative serum or urine pregnancy test minimum sensitivity 25 iv / l or equivalent units of hcg hcg within 24 hours prior to the start of nivolumab or nivolumab ipilimumab women must not be breastfeeding women who are not of childbearing potential i . e . who are postmenopausal or surgically sterile do not require contraception fcbp fcbp is defined as any female who has experienced menarche and who has not undergone surgical sterilization hysterectomy and / or bilateral oophorectomy or who is not postmenopausal menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the absence of other biological or physiological causes in addition women under the age of 55 must have a documented serum follicle stimulating hormone fsh level greater than 40 miu / ml if following initiation of the investigational product s it is subsequently discovered that a study subject is pregnant or may have been pregnant at the time of investigational product exposure including during at least 6 half lives after product administration the investigational product will be permanently discontinued in an appropriate manner e . g . dose tapering if necessary for subject safety the investigator must report this event and any outcomes by amendment through cancer therapy evaluation program ctep adverse event reporting system aers protocol required procedures for study discontinuation and follow up must be performed on the subject unless contraindicated by pregnancy e . g . x ray studies other appropriate pregnancy follow up procedures should be considered if indicated in addition the investigator must report and follow up on information regarding the course of the pregnancy including perinatal and neonatal outcome infants should be followed for a minimum of 8 weeks                                                                          ",1
"171","",NA,"or nursing women of child bearing potential fcbp must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation fcbp must have a screening negative serum or urine pregnancy test within 14 days of registration a second pregnancy test must be done within 24 hours prior to the start of the first cycle of study treatment women must not be breastfeeding women who are not of childbearing potential i . e . who are postmenopausal or surgically sterile do not require contraception fcbp fcbp is defined as any female who has experienced menarche and who has not undergone surgical sterilization hysterectomy and / or bilateral oophorectomy or who is not postmenopausal menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the absence of other biological or physiological causes in addition women under the age of 55 must have a documented serum follicle stimulating hormone fsh level greater than 40miu / ml                                                                                                                                                                                                                                                    ",1
"172","",NA,"women nursing women men or fcbp who are unwilling to employ adequate contraception or contraceptive method during this study and 6 months following the completion of chemotherapy treatments                                                                                                                                                                                                                                                                                                                                                                                                ",1
"173","",NA,"women nursing women men or fcbp who are unwilling to employ adequate contraception for the duration of study participation men and women should continue to use adequate birth control after the last administration of sorafenib and th 302 under the guidance of their treating physician                                                                                                                                                                                                                                                                                                                                                                                ",1
"174","",NA,"women nursing women fcbp who are unwilling to employ adequate contraception as determined by the treating physician                                                                                                                                                                                                                                                                                                                                                                                                            ",1
"176","",NA,"women fcbp who are unwilling to employ adequate contraception non barrier method                                                                                                                                                                                                                                                                                                                                                                                                               ",1
"180","",NA,"and not nursing for fcbp only a negative serum pregnancy test must be obtained within 14 days prior to registration fcbp must use adequate contraception from study start to one month after the last dose of protocol therapy adequate contraception is defined as hormonal birth control intrauterine device double barrier method or total abstinence men must practice complete abstinence or agree to use an adequate contraception method from study start to one month after the last dose of protocol therapy                                                                                                                                                                                                                                                                                                                                                ",1
"181","",NA,"or lactating                                                                                                                                                                                                                                                                                                                                                                                                                        ",1
